Pasithea Therapeutics (KTTA) Competitors $3.80 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends KTTA vs. VCNX, RNAZ, TLPH, AIM, CLDI, TENX, NRXP, MTEX, KZIA, and AWHShould you be buying Pasithea Therapeutics stock or one of its competitors? The main competitors of Pasithea Therapeutics include Vaccinex (VCNX), TransCode Therapeutics (RNAZ), Talphera (TLPH), AIM ImmunoTech (AIM), Calidi Biotherapeutics (CLDI), Tenax Therapeutics (TENX), NRx Pharmaceuticals (NRXP), Mannatech (MTEX), Kazia Therapeutics (KZIA), and Aspira Women's Health (AWH). These companies are all part of the "pharmaceutical products" industry. Pasithea Therapeutics vs. Vaccinex TransCode Therapeutics Talphera AIM ImmunoTech Calidi Biotherapeutics Tenax Therapeutics NRx Pharmaceuticals Mannatech Kazia Therapeutics Aspira Women's Health Pasithea Therapeutics (NASDAQ:KTTA) and Vaccinex (NASDAQ:VCNX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Which has more volatility and risk, KTTA or VCNX? Pasithea Therapeutics has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Vaccinex has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Is KTTA or VCNX more profitable? Vaccinex's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Pasithea TherapeuticsN/A -74.56% -67.62% Vaccinex N/A N/A -446.07% Which has higher valuation and earnings, KTTA or VCNX? Pasithea Therapeutics has higher earnings, but lower revenue than Vaccinex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPasithea Therapeutics$20K197.60-$15.96MN/AN/AVaccinex$356K14.32-$20.25M-$60.71-0.05 Do institutionals and insiders hold more shares of KTTA or VCNX? 23.9% of Pasithea Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 16.3% of Pasithea Therapeutics shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts prefer KTTA or VCNX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pasithea Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AVaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community favor KTTA or VCNX? Vaccinex received 121 more outperform votes than Pasithea Therapeutics when rated by MarketBeat users. Likewise, 60.00% of users gave Vaccinex an outperform vote while only 40.00% of users gave Pasithea Therapeutics an outperform vote. CompanyUnderperformOutperformPasithea TherapeuticsOutperform Votes240.00% Underperform Votes360.00% VaccinexOutperform Votes12360.00% Underperform Votes8240.00% Does the media refer more to KTTA or VCNX? In the previous week, Vaccinex had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Vaccinex and 0 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 0.00 equaled Vaccinex'saverage media sentiment score. Company Overall Sentiment Pasithea Therapeutics Neutral Vaccinex Neutral SummaryVaccinex beats Pasithea Therapeutics on 8 of the 11 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KTTA vs. The Competition Export to ExcelMetricPasithea TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.95M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E RatioN/A9.36112.5515.07Price / Sales197.60386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book0.175.324.645.01Net Income-$15.96M$153.56M$119.13M$225.46M7 Day Performance2.70%0.12%0.78%0.37%1 Month Performance-22.61%15.23%5.65%3.57%1 Year Performance-40.63%41.16%36.90%29.42% Pasithea Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KTTAPasithea TherapeuticsN/A$3.80flatN/A-47.9%$3.95M$20,000.000.003VCNXVaccinex1.4098 of 5 stars$2.95+5.7%N/A-76.9%$5.10M$356,000.00-0.0540News CoverageRNAZTransCode Therapeutics2.2573 of 5 stars$0.48+2.1%$3.00+525.0%-96.8%$8.29MN/A0.009TLPHTalphera2.4164 of 5 stars$0.92-2.1%$4.50+389.1%N/A$15.63M$650,000.00-1.4419Gap DownAIMAIM ImmunoTech1.3085 of 5 stars$0.26flat$3.00+1,049.0%-43.7%$15.32M$201,000.00-0.4620Gap UpCLDICalidi Biotherapeutics2.175 of 5 stars$1.35+14.4%$16.67+1,134.6%N/A$15M$50,000.000.0041Gap UpHigh Trading VolumeTENXTenax Therapeutics3.1976 of 5 stars$4.49+2.3%$170.67+3,705.3%-69.7%$14.97MN/A0.009News CoverageNRXPNRx Pharmaceuticals1.5874 of 5 stars$1.39+0.7%$31.50+2,174.4%-95.5%$14.89MN/A-0.512MTEXMannatech0.8721 of 5 stars$7.82flatN/A-9.5%$14.74M$122.38M-12.41250Upcoming EarningsAnalyst ForecastNews CoverageKZIAKazia Therapeutics1.6853 of 5 stars$5.52+2.2%$20.00+262.3%+35.7%$14.55M$20,000.000.0012AWHAspira Women's Health1.1892 of 5 stars$0.90flat$4.40+388.9%-80.8%$14.45M$9.15M-0.62110Analyst ForecastGap Up Related Companies and Tools Related Companies Vaccinex Alternatives TransCode Therapeutics Alternatives Talphera Alternatives AIM ImmunoTech Alternatives Calidi Biotherapeutics Alternatives Tenax Therapeutics Alternatives NRx Pharmaceuticals Alternatives Mannatech Alternatives Kazia Therapeutics Alternatives Aspira Women's Health Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KTTA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pasithea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KTTA Stock Alerts